Eli Lilly and Verve Therapeutics have announced a definitive agreement for Lilly to acquire Verve.  Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime.   Verve's lead programme (VERVE-102) is a potential first-in-class […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!